Editing Pfizer (section)

===2022 Inflating Prices fine===
In July 2022, UK antitrust authorities fined Pfizer £63 million for unfairly high priced drug that aids in controlling epileptic seizures. The Competition and Markets Authority stated that the company took advantage of loopholes by de-branding epilepsy drug Epanutin, by doing so the price of Epanutin's price was not regulated to the same standards the company are used to and therefore the price of the drug was raised. It was stated that over a four-year period, Pfizer had billed Epanutin for around 780% and 1,600% higher than its standard price.<ref>{{cite web |url=https://www.bloomberg.com/news/articles/2022-07-21/pfizer-flynn-fined-70-million-for-unfair-epilepsy-drug-prices#xj4y7vzkg|title=Pfizer, Flynn Fined £70 Million for Epilepsy Drug Prices|last=Browning|first=Jonny|date=21 July 2022|website=bloomberg.com|publisher=Bloomberg|access-date=27 July 2022}}</ref>